|
Prior to the merger of Fulcrum Pharmaceuticals and Ception Therapeutics, Dr. Evan Dick was V.P. of Operations and Business Development at Fulcrum. Evan's responsibilities at Fulcrum included R&D operations, licensing, strategic planning, and project management. Prior to joining Fulcrum, Evan was the Chief Executive Officer of Kereos, Inc., an early development stage biotechnology company. Kereos' molecularly targeted nanoparticle technology is being used to develop pioneering products for very early diagnosis and treatment of solid tumors, cardiovascular and cerebrovascular disease. As founding CEO, Evan took the company from academic concept through private equity placement and into corporate alliances. Evan's prior positions have included serving as the V.P. and General Manager of MedStrategy, Inc, a report arm of The Mattson Jack Group (MJG), an international healthcare consulting group. Prior to MedStrategy, Evan was COO of Cytotaxis, Inc., a NY-based biotech founded to commercialize a ligament specific growth factor discovered at Columbia University. Before that, Evan was Chairman, Central Nervous System Research for G.D. Searle & Company, a position he came to after being a member of the Departments of Ophthalmology and Pharmacology at the Washington University School of Medicine. | 